Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

This retrospective analysis conducted using data from patients enrolled onto the Herceptin Adjuvant has two objectives: The first is to evaluate the impact of the time interval between the end of adjuvant trastuzumab and distant recurrence (TDRI) upon overall survival (OS). The second is to describe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Metzger-Filho, Otto, de Azambuja, Evandro, Procter, Marion, Krieguer, Magalie, Smith, Ian, Baselga, Jose, Cameron, David, Untch, Michael, Jackisch, Christian, Bell, Richard, Gianni, Luca, Goldhirsch, Aron, Piccart, Martine, Gelber, Richard D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4947530/
https://ncbi.nlm.nih.gov/pubmed/26708471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3656-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados